Navigation Links
2-in-1 Test Signals Risk After Heart Attack
Date:12/4/2007

It measures nervous system and heart's electrical system

TUESDAY, Dec. 4 (HealthDay News) -- A test of two heart functions accurately spotted patients at highest risk of cardiac arrest or death as they recovered from a heart attack, Canadian researchers report.

"This is important because past studies, focusing on a single test, failed to identify most people at risk," said study lead author Dr. Derek V. Exner, associate professor of medicine at the University of Calgary. "We developed a simple method of identifying approximately twice as many people at risk. That means we can potentially save more lives."

The tests used in study are available now, although they aren't widely used, Exner said. "Theoretically, we can do them today if we chose to," he said. But the plan is to wait for the completion of additional trials, such as two large-scale studies now in the planning stage.

In the study, Exner and his colleagues had 322 people wear monitors for 18 to 24 hours a day, starting two to four weeks after they had suffered a heart attack. The researchers looked at the electrocardiograms recorded by the devices for an abnormality in heart rhythm called T-wave alternans, a symptom so subtle it can be detected only by computer analysis.

In addition to that measure of heart function, the electrocardiograms were also analyzed for the presence of heart rate turbulence, an abnormality of the autonomic nervous system that controls heart function.

Starting at 10 to 14 weeks after the heart attack, the presence of the two abnormalities clearly identified persons at increased risk. The 20 percent of study participants who had both abnormalities had more than six times the risk of cardiac arrest or death than other people in the study, the researchers said.

The findings are published in the Dec. 11 issue of the Journal of the American College of Cardiology.

Previous studies have shown that one abnormality or the other can increase cardiovascular risk, said Dr. David S. Rosenbaum, professor of medicine at Case Western Reserve University, who first reported on T-wave alternans in 1994.

"This is where this paper extends our knowledge," Rosenbaum said. "It shows that the two [irregularities] have a synergistic effect in a post-myocardial infarction [heart attack] population."

One application of the two-in-one testing could be in selecting persons who would be best helped by an implantable defibrillator, a device that delivers a shock to keep the heart beating normally when necessary. In the majority of cases today, Rosenbaum said, an implanted defibrillator just sits in the chest, because its emergency activity is never needed.

Exner said: "We have two large studies planned. One is where we have patients who are not indicated for defibrillators post-MI [myocardial infarction]. It is starting in May. The other study will include patients getting defibrillators because of a low ejection fraction," a weakened ability to pump blood.

Until these and other studies are done, "it's too early to start making treatment decisions" on the basis of the two combined tests, Exner said.

Rosenbaum said the new study does show "that when you combine these tests, you get a fairly robust prediction of outcomes. But like all good studies, it raises a lot of questions. It also requires validation in prospective trials."

More information

To learn more about implantable defibrillators, visit the American Heart Association.



SOURCES: Derek V. Exner, M.D., associate professor of medicine, University of Calgary, Canada; David S. Rosenbaum, M.D., professor, medicine and biomedical engineering, Case Western Reserve University, Cleveland; Dec. 11, 2007, Journal of the American College of Cardiology


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Work-Family Conflict Dogs Air Force Women After Deployment
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Stopping Statins After Stroke Doubles Death Risk
4. Billy Graham Home After Hospitalization:
5. Swelling After Knee Injury May Hinder Healing
6. Going on After Loss
7. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
8. Discover The Mutter Museum After Dark
9. Cialis Eases Erectile Dysfunction After Spinal Cord Injury
10. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
11. Pill Equals Injection in Preventing Clots After Hip Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2-in-1 Test Signals Risk After Heart Attack
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... STAT courier ... to be a convenient service for Texas, they are expanding their presence in Dallas. ... a hiring spree that will bring new jobs to the Dallas and Forth Worth ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology: